Tumor cell phenotype and heterogeneity differences in IDH1 mutant vs wild-type gliomas

Glioma is recognized to be a highly heterogeneous CNS malignancy, whose diverse cellular composition and cellular interactions have not been well characterized. To gain new clinical- and biological-insights into the genetically-bifurcated IDH1 mutant (mt) vs wildtype (wt) forms of glioma, we integrated multiplexed immunofluorescence single cell data for 43 protein markers across cancer hallmarks, in addition to cell spatial metrics, genomic sequencing and magnetic resonance imaging (MRI) quantitative features. Molecular and spatial heterogeneity scores for angiogenesis and cell invasion differ between IDHmt and wt gliomas irrespective of prior treatment and tumor grade; these differences also persisted in the MR imaging features of peritumoral edema and contrast enhancement volumes. Longer overall survival for IDH1mt glioma patients may reflect generalized altered cellular, molecular, spatial heterogeneity which manifest in discernable radiological manifestations.

[1]  S.s. Lu,et al.  Combined texture analysis of diffusion-weighted imaging with conventional MRI for non-invasive assessment of IDH1 mutation in anaplastic gliomas. , 2019, Clinical radiology.

[2]  Hairong Zheng,et al.  Multiregional radiomics profiling from multiparametric MRI: Identifying an imaging predictor of IDH1 mutation status in glioblastoma , 2018, Cancer medicine.

[3]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. , 2018, Neuro-oncology.

[4]  Xuejun Yang,et al.  Tumour cell dormancy as a contributor to the reduced survival of GBM patients who received standard therapy. , 2018, Oncology reports.

[5]  Zhihong Chen,et al.  Immune Microenvironment in Glioblastoma Subtypes , 2018, Front. Immunol..

[6]  H. Hricak,et al.  Background, current role, and potential applications of radiogenomics , 2018, Journal of magnetic resonance imaging : JMRI.

[7]  Xiaowei Chen,et al.  Computational de novo discovery of distinguishing genes for biological processes and cell types in complex tissues , 2018, PloS one.

[8]  Lucy F. Stead,et al.  Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium , 2018, Neuro-oncology.

[9]  S. Bae,et al.  Prediction of IDH1-Mutation and 1p/19q-Codeletion Status Using Preoperative MR Imaging Phenotypes in Lower Grade Gliomas , 2018, American Journal of Neuroradiology.

[10]  J. Graf,et al.  Characterizing the heterogeneity of tumor tissues from spatially resolved molecular measures , 2017, PloS one.

[11]  Raymond Y Huang,et al.  Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR Imaging , 2017, Clinical Cancer Research.

[12]  Jennie W. Taylor,et al.  Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma , 2017, Clinical Cancer Research.

[13]  J. Carpten,et al.  A method to reduce ancestry related germline false positives in tumor only somatic variant calling , 2017, BMC Medical Genomics.

[14]  Y. Kanemura,et al.  Mouse Models of Glioblastoma , 2017 .

[15]  Jill P. Mesirov,et al.  Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway , 2017, Nature.

[16]  Stuart L. Schreiber,et al.  Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition , 2017, Nature.

[17]  David T. W. Jones,et al.  Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery , 2017, Acta neuropathologica communications.

[18]  J. Costello,et al.  Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas , 2017, The Journal of clinical investigation.

[19]  E. Joekes,et al.  Ultrasound surveillance for hepatocellular carcinoma: service evaluation of a radiology-led recall system in a tertiary-referral centre for liver diseases in the UK. , 2017, Clinical radiology.

[20]  Shijie C. Zheng,et al.  A comparison of reference-based algorithms for correcting cell-type heterogeneity in Epigenome-Wide Association Studies , 2017, bioRxiv.

[21]  L. Parada,et al.  Cell of Origin and Cancer Stem Cells in Tumor Suppressor Mouse Models of Glioblastoma , 2016, Cold Spring Harbor symposia on quantitative biology.

[22]  J. Mercer,et al.  VEGF induces signalling and angiogenesis by directing VEGFR2 internalisation through macropinocytosis , 2016, Journal of Cell Science.

[23]  L. Cai,et al.  In Situ Transcription Profiling of Single Cells Reveals Spatial Organization of Cells in the Mouse Hippocampus , 2016, Neuron.

[24]  A. Butte,et al.  Digitally deconvolving the tumor microenvironment , 2016, Genome Biology.

[25]  Patrik L. Ståhl,et al.  Visualization and analysis of gene expression in tissue sections by spatial transcriptomics , 2016, Science.

[26]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[27]  Christos Davatzikos,et al.  Imaging genomics in cancer research: limitations and promises. , 2016, The British journal of radiology.

[28]  Baohui Liu,et al.  Expression of Ferritin Light Chain (FTL) Is Elevated in Glioblastoma, and FTL Silencing Inhibits Glioblastoma Cell Proliferation via the GADD45/JNK Pathway , 2016, PloS one.

[29]  Steven J. M. Jones,et al.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.

[30]  D. Tang,et al.  Ferroptosis: process and function , 2016, Cell Death and Differentiation.

[31]  S. Heiland,et al.  IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma , 2015, Scientific Reports.

[32]  Euiseok J. Kim,et al.  Adult Lineage-Restricted CNS Progenitors Specify Distinct Glioblastoma Subtypes. , 2015, Cancer cell.

[33]  Brian B. Avants,et al.  The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS) , 2015, IEEE Transactions on Medical Imaging.

[34]  A. Kaye,et al.  Molecular subtypes, stem cells and heterogeneity: Implications for personalised therapy in glioma , 2015, Journal of Clinical Neuroscience.

[35]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[36]  X. Zhuang,et al.  Spatially resolved, highly multiplexed RNA profiling in single cells , 2015, Science.

[37]  T. Cloughesy,et al.  Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma , 2015, Nature Reviews Cancer.

[38]  G. Nicholas,et al.  Radiological and Pathological Features Associated with IDH1-R132H Mutation Status and Early Mortality in Newly Diagnosed Anaplastic Astrocytic Tumours , 2015, PloS one.

[39]  Zhi-Xiong Lin,et al.  Peritumoral edema shown by MRI predicts poor clinical outcome in glioblastoma , 2015, World Journal of Surgical Oncology.

[40]  Emily J. Girard,et al.  Deep sequencing of multiple regions of glial tumors reveals spatial heterogeneity for mutations in clinically relevant genes , 2014, Genome Biology.

[41]  Eric C Leuthardt,et al.  Molecular and cellular heterogeneity: the hallmark of glioblastoma. , 2014, Neurosurgical focus.

[42]  Sang Joon Park,et al.  Glioma: Application of Whole-Tumor Texture Analysis of Diffusion-Weighted Imaging for the Evaluation of Tumor Heterogeneity , 2014, PloS one.

[43]  B. Welch,et al.  Management of intracranial aneurysms associated with arteriovenous malformations. , 2014, Neurosurgical focus.

[44]  Gary D Bader,et al.  Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity , 2015, Proceedings of the National Academy of Sciences.

[45]  Shawn M. Gillespie,et al.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.

[46]  J. Seoane,et al.  Glioblastoma Multiforme: A Look Inside Its Heterogeneous Nature , 2014, Cancers.

[47]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[48]  Se Hoon Kim,et al.  Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. , 2013, Cancer cell.

[49]  Renaud Gaujoux,et al.  CellMix: a comprehensive toolbox for gene expression deconvolution , 2013, Bioinform..

[50]  Qing Li,et al.  Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue , 2013, Proceedings of the National Academy of Sciences.

[51]  V. P. Collins,et al.  Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics , 2013, Proceedings of the National Academy of Sciences.

[52]  P. Costea,et al.  Comprehensive analysis of the genome transcriptome and proteome landscapes of three tumor cell lines , 2012, Genome Medicine.

[53]  T. Cloughesy,et al.  Relationship between Tumor Enhancement, Edema, IDH1 Mutational Status, MGMT Promoter Methylation, and Survival in Glioblastoma , 2012, American Journal of Neuroradiology.

[54]  Jens Rittscher,et al.  Coupled minimum-cost flow cell tracking for high-throughput quantitative analysis , 2011, Medical Image Anal..

[55]  Yoshitaka Narita,et al.  Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. , 2010, Genes & development.

[56]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[57]  Luis Serrano,et al.  Correlation of mRNA and protein in complex biological samples , 2009, FEBS letters.

[58]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[59]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[60]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[61]  A. Heimberger,et al.  The Role of Glioma Microenvironment in Immune Modulation: Potential Targets for Intervention , 2006 .

[62]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[63]  I. Ekiel,et al.  Metastasis-associated Protein S100A4 Induces Angiogenesis through Interaction with Annexin II and Accelerated Plasmin Formation* , 2005, Journal of Biological Chemistry.

[64]  Luca Regli,et al.  Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.

[65]  J. Brenton,et al.  Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging. , 2017, Clinical radiology.

[66]  [World Health Organization classification of tumours of the central nervous system: a summary]. , 2016, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[67]  D. Friedmann-Morvinski.  Glioblastoma heterogeneity and cancer cell plasticity. , 2014, Critical reviews in oncogenesis.

[68]  Benjamin M. Ellingson,et al.  Radiogenomics and Imaging Phenotypes in Glioblastoma: Novel Observations and Correlation with Molecular Characteristics , 2014, Current Neurology and Neuroscience Reports.